Global Contraceptive Devices Market 2015-2019
About Contraception Devices
Contraception methods can be temporary or permanent and are available for both men and women. Permanent methods include sterilization for women (tubal occlusion or hysteroscopy) and sterilization for men (vasectomy). Temporary methods are hormonal and non-hormonal. Hormonal methods include contraceptive transdermal patches, oral contraceptive pills, hormonal IUDs, vaginal rings, and vaginal implants. Non-hormonal methods include withdrawal methods, diaphragms, condoms, sponges, cervical caps, and non-hormonal IUDs. Condoms, diaphragms, sponges, and cervical caps are also referred to as barrier contraception methods.
Technavio's analysts forecast the global contraceptive devices market to grow at a CAGR of 4.88% over the period 2014-2019.
Covered in this Report
The report includes the present scenario and the growth prospects of the global contraceptive devices market for the period 2015-2019. To calculate the market size, we considered revenue generated from sales of various contraception devices.
Technavio's report, Global Contraceptive Devices Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global contraceptive devices market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.Key Regions
Technavio Announces the Publication of its Research Report – Global Contraceptive Devices Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Contraceptive Devices Market: Ansell, Actavis, Bayer, Church & Dwight and Merck & Co
Other Prominent Vendors in the market are: Agile Therapeutics, Caya, Condomi Health International, Fuji Latex, HLL Lifecare, Karex Industries, Lipocine, Mayer Laboratories, Medicines 360, Okamoto Industries, Reckitt Benckiser Group, Teva Pharmaceuticals, The Female Health Company and TodaySponge
Commenting on the report, an analyst from Technavio’s team said: “Recently, leading companies have introduced their diverse contraceptive drug and product portfolios in the market. These vendors undergo deals or form partnerships to develop or introduce new products with better efficacy and safety profiles. These strategic decisions help companies to generate revenue and acquire a significant share of the market. For instance, Actavis and Medicines360 collaborated to develop LILETTA, a levonorgestrel-releasing IUS that prevents pregnancy for up to three years. Starpharma and Okamoto Industries entered into a licensing agreement for the development of the VivaGel-coated condom. These strategic collaborations between leading and local companies benefit both of the parties involved: domestic firms gain access to diversified products, and global companies gain access to enhanced distribution and sales channels for the smooth distribution of their products.”
According to the report, unplanned pregnancies lead to unnecessary healthcare expenditures on abortions. Governments and NGOs are extensively promoting the use of contraceptive devices, along with family planning and birth control measures, to curb unplanned pregnancies. Organizations such as the APCOC, ESC, FIGO, and IPPF are conducting programs and implementing initiatives to spread awareness of contraceptive devices worldwide.
Further, the report states that the presence of low-cost generic contraceptives inhibits market growth.
Ansell, Actavis, Bayer, Church & Dwight,Merck & Co, Agile Therapeutics, Caya, Condomi Health International, Fuji Latex, HLL Lifecare, Karex Industries, Lipocine, Mayer Laboratories, Medicines 360, Okamoto Industries, Reckitt Benckiser Group, Teva Pharmaceuticals, The Female Health Company, TodaySponge